[ CAS No. 1429180-81-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 1429180-81-3 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1429180-81-3 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1429180-81-3 ]

SDS Specification

Alternatived Products of [ 1429180-81-3 ]

Product Details of [ 1429180-81-3 ]

CAS No. :	1429180-81-3	MDL No. :
Formula :	C₁₀H₁₂ClN₃O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	-
M.W :	241.67	Pubchem ID :	-
Synonyms :

Safety of [ 1429180-81-3 ]

Signal Word:	Danger	Class:	6.1
Precautionary Statements:	P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501	UN#:	2811
Hazard Statements:	H301-H311-H331	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 1429180-81-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1429180-81-3 ]

[ 1429180-81-3 ] Synthesis Path-Downstream 1~9

1
[ 1429180-81-3 ]
[ 68285-27-8 ]
[ 1429176-16-8 ]
[ 1429176-17-9 ]

Yield	Reaction Conditions	Operation in experiment
	In dimethyl sulfoxide; at 110℃; for 1.5h;	Examples 171 and 172A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (106 mg, 0.439 mmol) and 1 -(3-fluorophenyl)ethanamine (196 mg, 1 .41 mmol, 3.21 equiv) in DMSO (1 mL) was heated at 1 10 C for 1 ? h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 10 to 50%) provided (S)-3-(2-((/?)-1 -(3-fluorophenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one and (S)-3-(2-((S)-1-(3-fluorophenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2- one.Example 171 first eluted product (28 mg) 1 H NMR (400 MHz, CD3OD) ? 8.1 1 (d, J = 5.8 Hz, 1 H), 7.36 - 7.27 (m, 2 H), 7.16 (d, J = 7.6 Hz, 1 H), 7.07 (dt, J = 10, 2.0 Hz, 1 H), 6.92 - 6.88 (m, 1 H), 4.98 - 4.93 (m, 1 H), 4.42 (br s, 1 H), 4.32 (dd, J = 9.1 , 2.8 Hz, 1 H), 4.26 (t, J = 8.7 Hz, 1 H), 2.64 (dtd, J = 14, 7.1 , 3.5 Hz, 1 H), 1 .50 (d, J = 7.0 Hz, 3 H), 0.98 (d, J = 7.1 Hz, 3 H), 0.85 (d, J = 7.0 Hz, 3 H); HRMS(B) m/z 345.1729 (M + H)+. Example 172 second eluted product (22 mg) 1H NMR (400 MHz, CD3OD) ? 8.13 (d, J = 5.7 Hz, 1 H), 7.36 (d, J = 5.8 Hz, 1 H), 7.29 (td, J = 8.1 , 6.1 Hz, 1 H), 7.13 (d, J = 7.6 Hz, 1 H), 7.06 - 7.04 (m, 1 H), 6.94 - 6.87 (m, 1 H), 5.03 (q, J = 7.1 Hz, 1 H), 4.64 (br s, 1 H), 4.34 - 4.26 (m, 2 H), 1 .79 (br s, 1 H), 1 .50 (d, J = 7.1 Hz, 3 H), 0.70 (br s, 3 H), 0.58 (br s, 3 H); HRMS(B) m/z 345.1727 (M + H)+.

Reference： [1]Patent: WO2013/46136,2013,A1 .Location in patent: Page/Page column 163; 164

2
[ 1429180-81-3 ]
[ 55005-32-8 ]
[ 1429176-18-0 ]
[ 1429176-19-1 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 110℃; for 2h;	173; 174 Examples 173 and 174 Examples 173 and 174A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (90 mg, 0.37 mmol), /'Pr2NEt (0.455 mL, 2.61 mmol, 7.0 equiv) and 1-(biphenyl-4-yl)ethanamine hydrochloride (87 mg, 0.37 mmol) in DMSO (1 mL) was heated at 1 10 °C for 2 h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography(EtOAc/Heptane 10 to 50%) provided (S)-3-(2-((R)-1-(biphenyl-4-yl)ethylamino)pyrimidin- 4-yl)-4-isopropyloxazolidin-2-one and (S)-3-(2-((S)-1-(biphenyl-4-yl)ethylamino)pyrimidin- 4-yl)-4-isopropyloxazolidin-2-one.Example 173 first eluted product (17 mg) 1 H NMR (400 MHz, CD3OD) ? 8.1 1 (d, J = 5.8 Hz, 1 H), 7.59 - 7.54 (m, 4 H), 7.43 - 7.28 (m, 6 H), 5.01 (q, J = 6.8 Hz, 1 H), 4.49 (br s, 1 H), 4.32 (dd, J = 9.1 , 3.0 Hz, 1 H), 4.26 (t, J = 8.6 Hz, 1 H), 2.67 (dtd, J = 14, 7.0, 3.5 Hz, 1 H), 1.55 (d, J = 7.1 Hz, 3 H), 1.01 (d, J = 7.1 Hz, 3 H), 0.86 (d, J = 7.0 Hz, 3 H); HRMS(B) m/z 403.2141 (M + H)+.Example 174 second eluted product (21 mg) 1 H NMR (400 MHz, CD3OD) ? 8.14 (d, J = 5.8 Hz, 1 H), 7.58 - 7.52 (m, 4 H), 7.42 - 7.28 (m, 6 H), 5.06 (q, J = 7.1 Hz, 1 H), 4.63 (br s, 1 H), 4.34 - 4.25 (m, 2 H), 1 .79 (br s, 1 H), 1.55 (d, J = 7.1 Hz, 3 H), 0.65 (br s, 3 H), 0.53 (br s, 3 H); HRMS(B) m/z 403.2139 (M + H)+.

Reference： [1]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2013/46136, 2013, A1 Location in patent: Page/Page column 164

3
[ 1429180-81-3 ]
[ 74877-07-9 ]
[ 1429176-22-6 ]
[ 1429176-23-7 ]

Yield	Reaction Conditions	Operation in experiment
	In dimethyl sulfoxide; at 110℃; for 1.5h;	Examples 177 and 178A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (93 mg, 0.38 mmol) and 1 -(3,4-dichlorophenyl)ethanamine (73.1 mg, 0.385 mmol, 1 .0 equiv) in DMSO (1 mL) was heated at 1 10 C for 1 ? h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 10 to 50%) provided (S)-3-(2-((/?)-1 -(3,4-dichlorophenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2- one and (S)-3-(2-((S)-1-(3,4-dichlorophenyl)ethylamino)pyrimidin-4-yl)-4- isopropyloxazolidin-2-one.Example 177 first eluted product (21 mg) 1H NMR (400 MHz, CD3OD) ? 8.12 (d, J = 5.8 Hz, 1 H), 7.50 (d, J = 2.0 Hz, 1 H), 7.44 (d, J = 8.2 Hz, 1 H), 7.37 (d, J = 5.8 Hz, 1 H), 7.28 (dd, J = 8.6, 2.0 Hz, 1 H), 4.94 - 4.88 (m, 1 H), 4.43 (br s, 1 H), 4.35 - 4.26 (m, 2 H), 2.68 - 2.60 (m, 1 H), 1 .50 (d, J = 7.1 Hz, 3 H), 0.99 (d, J = 7.1 Hz, 3 H), 0.85 (d, J = 7.1 Hz, 3 H); HRMS(B) m/z 395.1035 (M + H)+.Example 178 second eluted product (28 mg) 1H NMR (400 MHz, CD3OD) ? 8.15 (d, J = 5.8 Hz, 1 H), 7.47 - 7.42 (m, 2 H), 7.37 (d, J = 5.8 Hz, 1 H), 7.25 (dd, J = 8.1 , 2.0 Hz, 1 H), 5.01 - 4.96 (m, 1 H), 4.61 (br s, 1 H), 4.34 - 4.26 (m, 2 H), 1.72 (br s, 1 H), 1 .50 (d, J = 7.1 Hz, 3 H), 0.67 (br s, 3 H), 0.60 (br s, 3 H); HRMS(B) m/z 395.1044 (M + H)+.

Reference： [1]Patent: WO2013/46136,2013,A1 .Location in patent: Page/Page column 165; 166

4
[ 832738-08-6 ]
[ 1429180-81-3 ]
[ 1429176-26-0 ]
[ 1429176-27-1 ]

Yield	Reaction Conditions	Operation in experiment
	In dimethyl sulfoxide at 110℃; for 2h;	181/182 Examples 181 and 182 Examples 181 and 182A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (44 mg, 0.18 mmol) and 1-(4-(1 H-pyrrol-1 -yl)phenyl)ethanamine (33.9 mg, 0.182 mmol, 1 equiv) in DMSO (1 mL) was heated at 1 10 °C for 2 h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 10 to 50%) provided (S)-3-(2-((R)-1 -(4-(1 H-pyrrol-1-yl)phenyl)ethylamino)pyrimidin-4-yl)-4- isopropyloxazolidin-2-one and (S)-3-(2-((S)-1-(4-(1 H-pyrrol-1 - yl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one.Example 181 first eluted product (18 mg) 1H NMR (400 MHz, CD3OD) ? 8.1 1 (d, J = 5.8 Hz, 1 H), 7.44 - 7.39 (m, 4 H), 7.35 (d, J = 5.9 Hz, 1 H), 7.13 (t, J = 2.2 Hz, 2 H), 6.24 (t, J = 2.0 Hz, 2 H), 5.02 - 4.96 (m, 1 H), 4.49 (br s, 1 H), 4.34 - 4.25 (m, 2 H), 2.66 (dtd, J = 14, 7.0, 3.3 Hz, 1 H), 1 .53 (d, J = 7.1 Hz, 3 H), 1 .00 (d, J = 7.1 Hz, 3 H), 0.86 (d, J = 7.1 Hz, 3 H); HRMS(B) m/z 392.2089 (M + H)+.Example 182 second eluted product (9 mg) 1H NMR (400 MHz, CD3OD) ? 8.14 (d, J = 5.8 Hz, 1 H), 7.39 (s, 4 H), 7.35 (d, J = 5.9 Hz, 1 H), 7.12 (t, J = 2.2 Hz, 2 H), 6.25 (t, J = 2.0 Hz, 2 H), 5.05 (q, J = 7.1 Hz, 1 H), 4.64 (br s, 1 H), 4.34 - 4.26 (m, 2 H), 1 .87 (br s, 1 H), 1 .53 (d, J = 7.1 Hz, 3 H), 0.68 (br s, 3 H), 0.57 (br s, 3 H); HRMS(B) m/z 392.2082 (M + H)+.

Reference： [1]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2013/46136, 2013, A1 Location in patent: Page/Page column 167

5
[ 936940-64-6 ]
[ 1429180-81-3 ]
[ 1429176-32-8 ]
[ 1429176-33-9 ]

Yield	Reaction Conditions	Operation in experiment
	In dimethyl sulfoxide at 110℃; for 1.5h;	187/188 Examples 187 and 188 Examples 187 and 188A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (96 mg, 0.40 mmol) and 1-(1-phenyl-1 H-pyrazol-4-yl)ethanamine (387 mg, 2.97 mmol, 5.2 equiv) in DMSO (1 .5 mL) was heated at 1 10 °C for 1 ? h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 20 to 80%) provided (S)-4-isopropyl-3-(2-((/?)-1-(1-phenyl-1 H-pyrazol-4-yl)ethylamino)pyrimidin-4- yl)oxazolidin-2-one and (S)-4-isopropyl-3-(2-((S)-1 -(1 -phenyl-1 H-pyrazol-4- yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one. Example 187 first eluted product (13 mg) 1H NMR (400 MHz, CD3OD) ? 8.16 (d, J = 5.8 Hz, 1 H), 8.10 (s, 1 H), 7.70 - 7.66 (m, 3 H), 7.48 - 7.43 (m, 2 H), 7.37 (d, J = 5.7 Hz, 1 H), 7.32 - 7.28 (m, 1 H), 5.20 (q, J = 6.6 Hz, 1 H), 4.75 (dt, J = 7.7, 4.0 Hz, 1 H), 4.40 - 4.33 (m, 2 H), 2.61 (dtt, J = 1 1 , 7.0, 3.6 Hz, 1 H), 1 .60 (d, J = 6.9 Hz, 3 H), 0.96 (d, J = 7.1 Hz, 3 H), 0.87 (d, J = 6.9 Hz, 3 H); HRMS(B) m/z 393.2029 (M + H)+.Example 188 second eluted product (1 1 mg) 1H NMR (400 MHz, CD3OD) ? 8.17 (d, J = 5.8 Hz, 1 H), 8.03 (s, 1 H), 7.68 - 7.62 (m, 3 H), 7.48 - 7.43 (m, 2 H), 7.37 (d, J = 5.8 Hz, 1 H), 7.32 - 7.27 (m, 1 H), 5.19 (q, J = 7.1 Hz, 1 H), 4.74 (dt, J = 8.5, 3.6 Hz, 1 H), 4.38 - 4.29 (m, 2 H), 2.37 - 2.33 (m, 1 H), 1 .60 (d, J = 7.1 Hz, 3 H), 0.79 (d, J = 7.1 Hz, 3 H), 0.73 (s, J = 7.1 Hz, 3 H); HRMS(B) m/z 393.2039 (M + H)+.

Reference： [1]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2013/46136, 2013, A1 Location in patent: Page/Page column 169; 170

6
[ 1049792-52-0 ]
[ 1429180-81-3 ]
[ 1429176-46-4 ]
[ 1429176-47-5 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide	201/202 Examples 201 and 202 Examples 201 and 202A solution of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (93 mg, 0.38 mmol), 1-(1-(4-methoxyphenyl)-1 H-pyrazol-4-yl)ethanamine hydrochloride (514 mg, 2.03 mmol, 5.3 equiv) and /'Pr2NEt (0.605 mL, 3.46 mmol, 9.0 equiv) in DMSO (1 .5 mL) was heated at 1 10 °C for 16 h. The reaction mixture was diluted with EtOAc (8 mL) and washed with water (30 mL). After separation, the aqueous phase was extracted with EtOAc (3 x 8 mL). Combined organics were dried over Na2S04, filtered and concentrated. Silica gel column chromatography (EtOAc/Heptane 10 to 70%) provided (S)-4-isopropyl-3-(2-((R)-1-(1-(4-methoxyphenyl)-1 H-pyrazol-4-yl)ethylamino)pyrimidin-4- yl)oxazolidin-2-one and (S)-4-isopropyl-3-(2-((S)-1-(1-(4-methoxyphenyl)-1 H-pyrazol-4- yl)ethylamino)pyrimidin-4-yl)oxazolidin-2-one. Example 201 first eluted product (17 mg) 1H NMR (400 MHz, CD3OD) ? 8.15 (d, J = 5.8 Hz, 1 H), 7.98 (s, 1 H), 7.63 (s, 1 H), 7.58 - 7.54 (m, 2 H), 7.37 (d, J = 5.8 Hz, 1 H), 7.03 - 6.99 (m, 2 H), 5.19 (q, J = 7.1 Hz, 1 H), 4.75 (dt, J = 7.7, 4.0 Hz, 1 H), 4.40 - 4.33 (m, 2 H), 3.83 (s, 3 H), 2.61 (dtd, J = 14, 7.1 , 3.5 Hz, 1 H), 1 .59 (d, J = 7.1 Hz, 3 H), 0.96 (d, J = 7.1 Hz, 3 H), 0.87 (d, J = 7.1 Hz, 3 H); HRMS(B) m/z 423.2138 (M + H)+.Example 202 second eluted product (18 mg) 1H NMR (400 MHz, CD3OD) ? 8.16 (d, J = 5.8 Hz, 1 H), 7.91 (s, 1 H), 7.58 - 7.53 (m, 3 H), 7.37 (d, J = 5.9 Hz, 1 H), 7.03 - 6.99 (m, 2 H), 5.18 (q, J = 6.7 Hz, 1 H), 4.76 - 4.72 (m, 1 H), 4.39 - 4.30 (m, 2 H), 3.83 (s, 3 H), 2.31 (br s, 1 H), 1 .59 (d, J = 7.1 Hz, 3 H), 0.80 (d, J = 7.1 Hz, 3 H), 0.73 (d, J = 7.1 Hz, 3 H); HRMS(B) m/z 423.214 (M + H)+.

Reference： [1]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2013/46136, 2013, A1 Location in patent: Page/Page column 174; 175

7
[ 3934-20-1 ]
[ 17016-83-0 ]
[ 1429180-81-3 ]
C₁₀H₁₂ClN₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1: 70% 2: 11%	With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃;	23 Intermediate III-5: (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one Example 23 Intermediate III-5: (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one A solution of (S)-4-phenyloxazolidin-2-one (3.0 g, 23.2 mmol) and 2,4-dichloropyrimidine (4.10 g, 27.5 mmol) in DMF (40 mL) was treated with NaH (60% in oil, 0.97 g, 24.3 mmol). The resulting mixture (yellow to red cloudy solution) was stirred at room temperature overnight. The reaction mixture was then diluted with EtOAc (200 mL), washed with saturated aqueous NH4Cl (75 mL) and brine (2*100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on an ISCO chromatography system (on a SiO2 column: eluted with 0 to 50% Hexanes/EtOAc gradient) to obtain the desired product III-5 as white solid (3.91 g, 70% yield) along with the other isomer III-5a (0.59 g, 11%). III-5: 1H NMR (300 MHz, CDCl3): δ ppm 8.46 (d, J=6.0 Hz, 1H), 8.18 (d, J 6.0 Hz, 1H), 4.80-4.75 (m, 1H), 4.42-4.34 (m, 2H), 2.66-2.54 (m, 1H), 0.99 (d, J=7.1 Hz, 3H), 0.87 (d, J=7.1 Hz, 3H). LCMS (method 3): Rt 11.62 min, m/z 242.1 [M+H]+. III-5a: 1H NMR (300 MHz, CDCl3): δ ppm 8.57 (d, J=5.2 Hz, 1H), 7.07 (d, J=5.2 Hz, 1H), 4.75-4.65 (m, 1H), 4.40-4.29 (m, 2H), 2.60-2.47 (m, 1H), 0.96 (d, J=6.9 Hz, 3H), 0.90 (d, J=6.9 Hz, 3H). LCMS (method 3): Rt 9.90 min, m/z 242.1 [M+H]+.

Reference： [1]Current Patent Assignee: FORMA THERAPEUTICS, INC. - US2016/83365, 2016, A1 Location in patent: Paragraph 0679; 0680

8
[ 1429180-81-3 ]
[ 55005-32-8 ]
[ 1429176-19-1 ]

Yield	Reaction Conditions	Operation in experiment
14%	With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 110℃; for 2h;

Reference： [1]Levell, Julian R.; Caferro, Thomas; Chenail, Gregg; Dix, Ina; Dooley, Julia; Firestone, Brant; Fortin, Pascal D.; Giraldes, John; Gould, Ty; Growney, Joseph D.; Jones, Michael D.; Kulathila, Raviraj; Lin, Fallon; Liu, Gang; Mueller, Arne; Van der Plas, Simon; Slocum, Kelly; Smith, Troy; Terranova, Remi; Touré, B. Barry; Tyagi, Viraj; Wagner, Trixie; Xie, Xiaoling; Xu, Ming; Yang, Fan S.; Zhou, Liping X.; Pagliarini, Raymond; Cho, Young Shin [ACS Medicinal Chemistry Letters, 2017, vol. 8, # 2, p. 151 - 156]

9
[ 3934-20-1 ]
[ 17016-83-0 ]
[ 1429180-81-3 ]

Yield	Reaction Conditions	Operation in experiment
74.1%	With sodium hydride In N,N-dimethyl-formamide at 0℃; for 4h;	3.1.1. Synthesis of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) To a mixture of 2,4-dichloropyrimidine (1.00 g, 6.71 mmol) and (S)-4-isopropyl-oxazolidin-2-one (867 mg, 6.71 mmol) in 7 mL anhydrousDMF, a solution of NaH (322 mg, 13.43 mmol) in DMF was addeddropwise under ice bath. The mixture was stirred for 4 h at 0 °C till itscompletion monitored by TLC. The reaction mixture was poured intoice water and the organic layer was collected with EtOAc, washed withsaturated NaHCO3 solution and dried with anhydrous Na2SO4.Purification of the crude product by rapid column chromatography(Petroleum: EtOAc=15:1, v:v) to afford the intermediate 3 as whitesolid (1.2 g, yield 74.1%). 1H NMR (500 MHz, CDCl3)δ 8.52 (d, J=5.8 Hz, 1H), 8.23 (d, J=5.8 Hz, 1H), 4.94-4.77 (m, 1H), 4.50-4.26(m, 2H), 2.72-2.55 (m, 1H), 1.04 (d, J=7.0 Hz, 3H), 0.93(d,J=7.0 Hz, 3H).
73%	With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃;	1.1 (1) Synthesis of (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one In an ice bath, NaH (60% in mineral oil, 520 mg, 13.0 mmol) was added in batches to a solution of (S)-4-(S)-4-isopropyloxazolidin-2-one (1.50 g, 11.6 mmol) and 2,4-dichloropyrimidine (1.90 g, 12.8 mmol) in DMF. The resulting yellow suspension was stirred overnight at room temperature. Then the mixture was poured into water (150 mL) and extracted with EtOAc (70 mL*3). The combined organic layer was washed with brine (70 ml), dried over MgSO4 and concentrated. The crude product was purified by column chromatography (petroleum ether: EtOAc = 5:1) to obtain the title compound (2.05 g, yield 73%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 6.0 Hz, 1H), 8.18 (d, J = 6.0 Hz, 1H), 4.81-4.77 (m, 1H), 4.43-4.34 (m, 2H), 2.64-2.56 (m, 1H), 0.99 (d, J = 7.2 Hz, 3H), 0.88 (d, J = 7.2 Hz, 3H)
62%	With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 2h;

40.4%

With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 12.0833h; Inert atmosphere;

(S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A solution of (S)-4- isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0 °C under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added to the solution. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) as a white solid (4 g, 40.4 %). MS m/z 242.09 [M+H]+.

Reference： [1]Jia, Panli; Wu, Yao; Du, Hongzhi; Yang, Lijun; Zhang, Zhibo; Ma, Tianfang; Li, Sun; Yuan, Shengtao; Lu, Ligong; Zha, Xiaoming [European Journal of Pharmaceutical Sciences, 2019, vol. 140]
[2]Current Patent Assignee: SHANGHAI EPITAS BIOTECHNOLOGY; EPITAS BIOSCIENCES SHANGHAI; SHANGHAI CUSTARD BIOTECHNOLOGY LTD - EP3964508, 2022, A1 Location in patent: Paragraph 0144-0146
[3]Levell, Julian R.; Caferro, Thomas; Chenail, Gregg; Dix, Ina; Dooley, Julia; Firestone, Brant; Fortin, Pascal D.; Giraldes, John; Gould, Ty; Growney, Joseph D.; Jones, Michael D.; Kulathila, Raviraj; Lin, Fallon; Liu, Gang; Mueller, Arne; Van der Plas, Simon; Slocum, Kelly; Smith, Troy; Terranova, Remi; Touré, B. Barry; Tyagi, Viraj; Wagner, Trixie; Xie, Xiaoling; Xu, Ming; Yang, Fan S.; Zhou, Liping X.; Pagliarini, Raymond; Cho, Young Shin [ACS Medicinal Chemistry Letters, 2017, vol. 8, # 2, p. 151 - 156]
[4]Current Patent Assignee: ISOCURE BIOSCIENCES - WO2018/118793, 2018, A1 Location in patent: Paragraph 00116; 00125; 00132; 00139; 00143

Same Skeleton Products

Related Products

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1429180-81-3 ] {[proInfo.proName]}

Quality Control of [ 1429180-81-3 ]

Related Doc. of [ 1429180-81-3 ]

Product Details of [ 1429180-81-3 ]

Safety of [ 1429180-81-3 ]

Application In Synthesis of [ 1429180-81-3 ]

[ 1429180-81-3 ] Synthesis Path-Downstream 1~9

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry